

Supplementary Fig S3






Fig S3. Loss of ATF3 impairs p53 activation by doxorubicin and actinomycin D treatments. (A) Wild-type (WT) or ATF3-null MEFs (-/-) were treated with doxorubicin (DOX -0.4 μ g/ml) or actinomycin D (AD-2 nM) for 24 h. Cell lysates were subjected to Western blotting. (B) E1A-infected wild-type or ATF3-null MEFs were treated without (Ctrl), or with DOX for 34 h (34 h), and the percentage of apoptotic cells was determined by FACS analysis. (C) Wild-type or ATF3-null MEFs were treated with actinomycin D for 12 h, and then labeled with BrdU for 3 h. BrdU positive cells representing cells in S phase were then counted.